Simon Timothy Abrams

Simon Timothy Abrams

Auto-generated profile, based on publicly available information

Simon Timothy Abrams

Department of Clinical Infection, Microbiology and Immunology University of Liverpool Liverpool UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
JSJeremy Schofield
Jeremy Schofield
SASimon Timothy Abrams
Simon Timothy Abrams
RJRosalind E. Jenkins
Rosalind E. Jenkins
SLSteven Lane
Steven Lane
GWGuozheng Wang
Guozheng Wang
CTCheng Hock Toh
Cheng Hock Toh
Microclots have been associated with various conditions, including postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. They have been postulated to be amyloid-fibrin(ogen) aggregates, but their role as a prognostic biomarker remains unclear. To examine their possible clinical utility, blood samples were collected for the first 96 hours from critically ill patients (n = 104) admitted to the intensive care unit (ICU). Detection was by staining platelet-poor plasma samples with thioflavin T and visualized by fluorescent microscopy. Image J software was trained to identify and quantify microclots, which were detected in 44 patients (42.3%) on ICU admission but not in the remaining 60 (57.7%) or the 20 healthy controls (0.0%). Microclots on admission to ICU were associated with a primary diagnosis of sepsis (microclots present in sepsis, 23/44 [52.3%] vs microclots absent in sepsis, 19/60 [31.7%]; P = .044). Multicolor immunofluorescence demonstrated that microclots consisted of amyloid-fibrinogen aggregates, which was supported by proteomic analysis. Patients with either a high number or larger-sized microclots had a higher likelihood of developing disseminated intravascular coagulation (odds ratio [OR], 51.4; 95% confidence interval [CI], 6.3-6721.1; P < .001) and had an increased probability of 28-day mortality (OR, 5.3; 95% CI, 2.0-15.6; P < .001). This study concludes that microclots, as defined by amyloid-fibrin(ogen) aggregates, are potentially useful in identifying sepsis and predicting adverse coagulopathic and clinical outcomes.

1 November 2017 in Pancreatology
Verified
Journal Article
Closed access
Peter SzatmaryPeter Szatmary
Peter Szatmary
TLTingting Liu
Tingting Liu
SASimon T. Abrams
Simon T. Abrams
SVSvetlana Voronina
Svetlana Voronina
LWLi Wen
Li Wen
RSRobert Sutton
Robert Sutton

1 July 2025 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
PDF file
PNPhillip Lindsay Ross Nicolson
Phillip Lindsay Ross Nicolson
SASimon T Abrams
Simon T Abrams
GAGayatri Amirthalingam
Gayatri Amirthalingam
KBKevin Brown
Kevin Brown
RBRichard J Buka
Richard J Buka
MPMunir Pirmohamed
Munir Pirmohamed
Background: Thrombosis with thrombocytopenia syndrome is a rare condition known to occur spontaneously or after heparin use. With the advent of COVID-19 vaccines during the pandemic, thrombosis with thrombocytopenia syndrome cases emerged post administration of adenoviral vaccines, termed vaccine-induced immune thrombosis and thrombocytopenia. In response, the thrombosis with thrombocytopenia syndrome consortium was formed to deepen our understanding of this syndrome post vaccination. Methods: The consortium employed a comprehensive approach across five work packages. This included designing cohort studies covering the entire English population and analysing local linked regional data sets to detect thrombosis with thrombocytopenia syndrome occurrences in real time. Various patient and healthy control specimens, including those from vaccinated individuals, underwent testing for antiplatelet factor 4 antibodies using three different assays. Patients who developed vaccine-induced immune thrombosis and thrombocytopenia after the AstraZeneca (AZD1222) COVID-19 vaccine underwent whole-genome and ribonucleic acid sequencing to identify genetic susceptibility factors. Multiple studies were conducted to investigate the mechanism of antiplatelet factor 4 antibody formation, including assessments of adenoviral vector structure and binding to platelet factor 4. Detailed studies were also conducted to understand the immune response to vaccines, the role of immune complexes involving platelet factor 4 and their effects on proinflammatory cytokines, neutrophil extracellular traps and platelets in the pathogenesis of the syndrome. Results: Cohort studies revealed a higher risk of arterial and venous thromboses after COVID-19 infection compared to vaccination. Specifically, regarding vaccines, the risk of thrombosis and/or thrombocytopenia was higher after the first dose of the AZD1222 vaccine but not with subsequent doses of. Regional linked data indicated that real-time ascertainment of diseases across multiple acute hospital sites’ secure data environments is not yet feasible at scale. The overall background seroprevalence of antiplatelet factor 4 antibodies was low in healthy individuals, vaccinated individuals and those infected with COVID-19. Whole-genome sequencing did not identify significant variants predisposing to vaccine-induced immune thrombosis and thrombocytopenia, with ongoing work on ribonucleic acid sequencing. An electrostatic interaction between the hexon hypervariable regions of the ChAdOx1 capsid and platelet factor 4 was suggested as a possible mechanism for antiplatelet factor 4 antibody development. Strong immune response drove the formation of neutrophil extracellular traps, significant inflammatory responses and clot formation in distant organs. Platelet activation post immune complex formation against platelet factor 4 was dependent on FcγRIIa but independent of complement, also occurring through binding with c-Mpl. T-cell reactivity against the AZD1222 vaccine indicates potential cross-reactivity with prevalent human adenoviruses. Conclusions: The consortium’s comprehensive work has uncovered new potential mechanisms of vaccine-induced immune thrombosis and thrombocytopenia and identified novel biomarkers and therapeutic strategies for further development and validation. This is crucial, as the combination of thrombosis and thrombocytopenia, alongside antiplatelet factor 4 antibodies, can occur without exposure to heparin or adenovirus vaccines. Future considerations: Recommendations include the development of a national reference laboratory and registry for diagnosis and further study of thrombosis with thrombocytopenia syndrome; future vaccine development using the adenoviral vector platform to focus on the reduction of the electrostatic interaction between viral hexons and platelet factor 4; international genomics collaboration; and studies focused on understanding the symptoms suffered by patients as well as strategies to ameliorate them. Limitations: Direct identification of vaccine-induced immune thrombosis and thrombocytopenia patients was hindered by poor recording. The rarity of vaccine-induced immune thrombosis and thrombocytopenia limited the number of patients recruited for genomic and mechanistic studies. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR135073.

16 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDagmara McGuinness
Dagmara McGuinness
CJCarla Johnson
Carla Johnson
LSLeandro Lemgruber Soares
Leandro Lemgruber Soares
FBFadil Bidmos
Fadil Bidmos
EYEdwin Yates
Edwin Yates
CMChristopher A. Moxon
Christopher A. Moxon
Vascular injury and coagulopathy are key drivers of mortality in bacterial sepsis. In Neisseria meningitidis infection, endothelial adhesion and thrombosis cause the characteristic petechial rash and, in the most severe cases, purpura fulminans. Although antibiotics rapidly kill bacteria, inflammation and vascular injury often persist or worsen after bacterial clearance, suggesting ongoing toxicity from released bacterial components. Here we identify bacterial histone-like proteins (HLPs), small positively charged DNA-binding proteins conserved across bacterial species, as previously unrecognized mediators of vascular damage. In vitro HLPs are released following antibiotic exposure, disrupting endothelial integrity. In patients with severe sepsis, they are detectable in plasma and tissue, colocalising with areas of vascular leak and coagulopathy. Non-anticoagulant heparins and anti-HLP antibodies neutralize HLP-induced endothelial disruption and toxicity in vitro and in vivo . These findings reveal HLPs as antibiotic-released bacterial toxins and suggest new therapeutic strategies to prevent vascular injury in sepsis. One sentence summary: Antibiotic treatment of meningococcal and other sepsis causative bacteria triggers the release of histone-like proteins (HLPs) that damage the endothelium and drive coagulopathy, but these effects can be neutralized by non-anticoagulant heparins or anti-HLP antibodies.

11 November 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
JSJ. Schofield
J. Schofield
SAS. Abrams
S. Abrams
YAY. Alhamdi
Y. Alhamdi
SAStuart Ainsworth
Stuart Ainsworth
CEC. Evans
C. Evans
CTCheng Hong Toh
Cheng Hong Toh

9 September 2026 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CDCatherine B. Ducker
Catherine B. Ducker
MPMegan V. Preece
Megan V. Preece
JSJeremy Schofield
Jeremy Schofield
CPCharis Pericleous
Charis Pericleous
MLMike Laffan
Mike Laffan
Deepa J ArachchillageDeepa J Arachchillage
Deepa J Arachchillage
Summary: Inflammation contributes to primary antiphospholipid syndrome (PAPS) pathogenesis, but cytokine profiles and associated thrombotic phenotypes remain incompletely defined. A panel of 20 cytokines, chemokines and endothelial activation markers was analysed in 37 PAPS patients on stable anticoagulation and 12 healthy controls (HC). We compared concentrations between groups and performed unsupervised hierarchical clustering and principal component analysis (PCA) to identify inflammatory subgroups. Compared with HC, patients with PAPS exhibited significantly elevated levels of 14/20 analytes: granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interferon (IFN)‐γ, interleukin (IL)‐1α, IL‐1β, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17a, tumour necrosis factor‐α (TNF‐α), intercellular adhesion molecule‐1 (ICAM‐1), P‐selectin and macrophage inflammatory protein‐1β (MIP1β) (all p < 0.05). Unsupervised clustering identified three inflammatory antiphospholipid syndrome (APS) subgroups distinct from HC. A core cytokine signature comprising GM‐CSF, IL‐6, IL‐10, IL‐12p70, IL‐13 and TNF‐α was elevated across all APS clusters. One cluster, enriched for arterial thrombosis, demonstrated a more pronounced inflammatory phenotype, with increased IFN‐α. Comparison of phenotypes showed significantly higher concentrations of GM‐CSF, IFN‐α, IL‐1α, IL‐4, IL‐6, IL‐10, IL‐17a and TNF‐α in arterial versus venous thrombosis. Our findings demonstrate widespread cytokine dysregulation and distinct inflammatory subgroups in PAPS, with arterial thrombosis showing stronger inflammation than venous thrombosis, supporting divergent thrombo‐inflammatory mechanisms and potential precision immunomodulatory therapeutic targets.